Related Experiment Videos
[Transferability of vancomycin to cerebrospinal fluid in rabbits with meningitis caused by Staphylococcus aureus]
Abstract:
The transferability of vancomycin (VCM) to cerebrospinal fluid (CSF) was studied employing rabbits with experimental meningitis caused by Staphylococcus aureus. VCM was administered intravenously for 30 minutes at a dose level of 30 mg/kg. Serum concentration reached a maximum of 75 +/- 3.80 micrograms/ml (mean +/- S.E.) at the completion of administration (i.e., 30 minutes) and CSF concentration reached a maximum of 2.4 +/- 0.39 micrograms/ml at 60 minutes. Pharmacokinetic parameters calculated from this concentration-time curve were as follows: Cmax (CSF/Serum) 3.21%, AUC (CSF/Serum) 2.39% between 15 and 60 minutes, 3.99% between 15 and 120 minutes, and 4.40% between 15 and 150 minutes. T 1/2 for VCM in CSF: 143 minutes, T1/2 (CSF/Serum):2.09. Based on this investigation, VCM appears to be effective in the treatment of meningitis caused by MRSA (Methicillin-resistant S. aureus).
Insights
Vancomycin (VCM) effectively transfers to cerebrospinal fluid (CSF) in rabbits with Staphylococcus aureus meningitis. This indicates VCM
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Infectious Diseases and Microbiology
Context:
- Meningitis, a serious central nervous system infection, often requires effective antibiotic penetration into the cerebrospinal fluid (CSF).
- Staphylococcus aureus, including Methicillin-resistant Staphylococcus aureus (MRSA), is a significant cause of bacterial meningitis.
Purpose:
- To evaluate the transferability and pharmacokinetic profile of vancomycin (VCM) into the CSF in a rabbit model of experimental meningitis.
- To determine the efficacy of VCM for treating meningitis caused by Staphylococcus aureus, particularly MRSA.
Summary:
- Intravenous administration of vancomycin (30 mg/kg) in rabbits with Staphylococcus aureus meningitis resulted in measurable CSF concentrations.
- Key pharmacokinetic parameters, including CSF/serum ratios for Cmax and AUC, and CSF half-life (T1/2), were calculated.
- Maximum CSF concentration of VCM was observed at 60 minutes post-administration.
Impact:
- The study suggests that vancomycin achieves adequate concentrations in the CSF, supporting its potential clinical utility.
- Findings provide evidence for the effectiveness of vancomycin in treating MRSA meningitis.